CMI_DigiBlogExplorer

Rare disease drugs, also known as orphan drugs, are simply drugs developed with no connection to any previous medical use in humans, and thus would not be profitable enough to make any profits from manufacture without governmental support. However, the conditions for obtaining these drugs are quite demanding. This is because the companies that develop them are generally those specializing in research and development of medicines for rare diseases. Thus, in order to receive financing from the government for the research and development of these rare drugs, these companies must prove beyond reasonable doubt that their drugs can be useful for humans.   The companies attempting to market rare disease drugs require to undergo rigorous testing. This testing procedure can take many months or even years, depending on the condition with which the company is seeking to treat and its profitability level. Often, it is the long duration of testing that hampers the development of drugs intend...

  There are six to seven thousand to eight thousand rare diseases presently affecting a total patient population of about 350 million worldwide. Large pharmaceutical companies have set their eyes on creating orphan drugs for treating such rare diseases. There are more than 7 thousand known rare diseases that affect an average global patient population. Of these, AIDS is the most common disease, accounting for more than a million deaths annually   However, rare disease drugs discovery can be an expensive affair because the companies involved in its discovery processes have to invest huge amounts in research and production of such medicines. The costs of producing these medicines can be quite high. Production can take up to several years, making it extremely expensive. Moreover, because of their rarity, drugs which have no known uses in humans can be very expensive to produce. The difficulty that faced while looking for rare disease drugs during the initial stages...